Publications: Priv.-Doz. Dr. med. J. Rech
- IgA anti-citrullinated protein antibodies are associated with flares during DMARD tapering in rheumatoid arthritis. Rheumatology (Oxford). 2022;61(5): 2124-2131
- High rates of therapeutic changes in patients with psoriatic arthritis receiving treatment with disease-modifying antirheumatic drugs: A cross-sectional study. Mod Rheumatol. 2022;32(1): 87-95
- Three generations of suffering: cryopyrin-associated periodic syndrome with NLRP3 mutation in a family. J Dtsch Dermatol Ges. 2022;20(1): 110-112
- Association of Structural Entheseal Lesions With an Increased Risk of Progression From Psoriasis to Psoriatic Arthritis. Arthritis Rheumatol. 2022;74(2): 253-262
- Microstructural Bone Changes Are Associated With Broad-Spectrum Autoimmunity and Predict the Onset of Rheumatoid Arthritis. Arthritis Rheumatol. 2022;74(3): 418-426
- Long-term B-lymphocyte depletion and remission of granulomatosis with polyangiitis after two courses of rituximab treatment. Rheumatology (Oxford). 2021;60(5): e162-e164
- Herpes simplex infection in a patient with rheumatoid arthritis treated with baricitinib: a case report. Rheumatology (Oxford). 2021;60(4): e122-e123
- SPATIOTEMPORAL DYNAMICS OF BONE LOSS BEFORE AND AFTER THE ONSET OF RHEUMATOID ARTHRITIS Ann Rheum Dis. 2021;80 Suppl 1(): 88-89
- Prediction of response to Certolizumab-Pegol in rheumatoid arthritis (PreCePRA) by functional MRI of the brain - Study protocol for a randomized double-blind controlled study. Contemp Clin Trials Commun. 2021;22():
- ASSOCIATION OF ANTI-CITRULLINATED PROTEIN ANTIBODIES OF IgA SUBCLASSES WITH SUSTAINED REMISSION AND FLARE IN RHEUMATOID ARTHRITIS Ann Rheum Dis. 2021;80 Suppl 1(): 461-461
- Proteomic Approaches to Defining Remission and the Risk of Relapse in Rheumatoid Arthritis. Front Immunol. 2021;12():
- TREATMENT TAPERING AND WITHDRAWAL IN RHEUMATOID ARTHRITIS WITH STABLE REMISSION - FINAL ANALYSIS OF THE RETRO STUDY Ann Rheum Dis. 2021;80 Suppl 1(): 194-195
- Sustained clinical remission under infliximab/rituximab combination therapy in a patient with granulomatosis with polyangiitis. Auto Immun Highlights. 2021;12(1):
- Autoinflammation leading to autoimmunity in adult-onset Still's disease: more than simple coincidence? Eur J Med Res. 2021;26(1):
- Genetic Analysis of MPO Variants in Four Psoriasis Subtypes in Patients from Germany. J Invest Dermatol. 2021;141(8): 2079-2083
- Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial Lancet Rheumatol.. 2021;3(11): E767-E777
- Advanced machine learning for predicting individual risk of flares in rheumatoid arthritis patients tapering biologic drugs. Arthritis Res Ther. 2021;23(1):
- Secukinumab Efficacy in Psoriatic Arthritis: Machine Learning and Meta-analysis of Four Phase 3 Trials. J Clin Rheumatol. 2021;27(6): 239-247
- Correspondence on 'Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort'. Ann Rheum Dis. 2021;80(10):
- Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study. Rheumatology (Oxford). 2021;60(8): 3851-3861
- PATIENTS AT RISK FOR RA SHOW THE SAME AMOUNT OF ACUTE SOLUBLE CARTILAGE DEGRADATION MARKERS AFTER PHYSICAL ACTIVITY COMPARED TO PATIENTS WITH ESTABLISHED RA Ann Rheum Dis. 2021;80 Suppl 1(): 420-421
- LONG-TERM SAFETY AND EFFECTIVENESS OF CANAKINUMAB IN CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS)-30-MONTH DATA FROM THE RELIANCE REGISTRY Ann Rheum Dis. 2021;80 Suppl 1(): 50-51
- Bone microstructure and volumetric bone mineral density in patients with hyperuricemia with and without psoriasis. Osteoporos Int. 2020;31(5): 931-939
- A Detailed Analysis of the Association between Urate Deposition and Erosions and Osteophytes in Gout. ACR Open Rheumatol. 2020;2(10): 565-572
- TIME TO FLARE AND GLUCOCORTICOID EXPOSURE IN PATIENTS WITH NEW-ONSET VERSUS RELAPSING GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB OR PLACEBO PLUS PREDNISONE TAPERING: 3-YEAR RESULTS FROM A RANDOMIZED CONTROLLED PHASE 3 TRIAL Ann Rheum Dis. 2020;79 Suppl 1(): 20-20
- Dietary Short-Term Fiber Interventions in Arthritis Patients Increase Systemic SCFA Levels and Regulate Inflammation. Nutrients. 2020;12(10):
- Bone Mass, Bone Microstructure and Biomechanics in Patients with Hand Osteoarthritis. J Bone Miner Res. 2020;35(9): 1695-1702
- Hidradenitis Suppurativa and Concurrent Psoriasis: Comparison of Epidemiology, Comorbidity Profiles, and Risk Factors. Dermatol Ther (Heidelb). 2020;10(4): 721-734
- Quantification of hand muscle volume and composition in patients with rheumatoid arthritis, psoriatic arthritis and psoriasis. BMC Musculoskelet Disord. 2020;21(1):
- T2 Mapping as a New Method for Quantitative Assessment of Cartilage Damage in Rheumatoid Arthritis. J Rheumatol. 2020;47(6): 820-825
- STRUCTURAL ENTHESEAL LESIONS IN PSORIASIS PATIENTS ARE ASSOCIATED WITH AN INCREASED RISK OF PROGRESSION TO PSORIATIC ARTHRITIS - A PROSPECTIVE COHORT STUDY Ann Rheum Dis. 2020;79 Suppl 1(): 33-34
- TYPE 3 INNATE LYMPHOID CELLS ARE KEY DRIVERS OF PSORIATIC ARTHRITIS Ann Rheum Dis. 2020;79 Suppl 1(): 1119-1120
- Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study Lancet Rheumatol.. 2020;2(4): E227-E235
- Longitudinal Change in the Central Nervous System Pain Response After Treatment with Certolizumab or Placebo. a Post-hoc Analysis from the Pre-CEPRA Trial Arthritis Rheumatol. 2020;72 Suppl 10():
- IgA subclasses have different effector functions associated with distinct glycosylation profiles. Nat Commun. 2020;11(1):
- Anti-granulocyte-macrophage colony-stimulating factor antibody otilimab in patients with hand osteoarthritis: a phase 2a randomised trial Lancet Rheumatol.. 2020;2(10): E623-E632
- FINE STRUCTURE ANALYSIS OF THE INTER-RELATION BETWEEN TOPHUS DEPOSITION AND BONE LESIONS IN GOUT USING A COMBINATION OF DUAL ENERGY AND HIGH-RESOLUTION CT Ann Rheum Dis. 2020;79 Suppl 1(): 1232-1232
- Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. PLoS ONE. 2020;15(1):
- Secukinumab leads to shifts from stage-based towards response-based disease clusters-comparative data from very early and established psoriatic arthritis. Arthritis Res Ther. 2020;22(1):
- S2k guidelines: management of large-vessel vasculitis Z Rheumatol. 2020;79 Suppl 3(SUPPL 3): 67-95
- [S2k guidelines (executive summary): management of large-vessel vasculitis]. Z Rheumatol. 2020;79(9): 937-942
- Similar Impact of Psoriatic Arthritis and Rheumatoid Arthritis on Objective and Subjective Parameters of Hand Function. ACR Open Rheumatol. 2020;2(12): 734-740
- Structural Entheseal Lesions in Psoriasis Patients Are Associated with an Increased Risk Ofprogression to Psoriatic Arthritis - A Prospective Cohort Study Arthritis Rheumatol. 2020;72 Suppl 10():
- Brain fMRI Predicts Responses to Certolizumab Pegol in RA. an International, Multi-center, Randomized, Double-blind, Placebocontrolled Trial (PreCePRA) Arthritis Rheumatol. 2020;72 Suppl 10():
- LONGITUDINAL CHANGE IN THE CENTRAL NERVOUS SYSTEM PAIN RESPONSE AFTER TREATMENT WITH CERTOLIZUMAB OR PLACEBO. A POST-HOC ANALYSIS FROM THE PRECEPRA TRIAL Ann Rheum Dis. 2020;79 Suppl 1(): 77-78
- A set of serum markers detecting systemic inflammation in psoriatic skin, entheseal, and joint disease in the absence of C-reactive protein and its link to clinical disease manifestations. Arthritis Res Ther. 2020;22(1):
- Effects of Conventional Uric Acid-Lowering Therapy on Monosodium Urate Crystal Deposits Arthritis Rheumatol. 2020;72(1): 150-156
- Rare Loss-of-Function Mutation in SERPINA3 in Generalized Pustular Psoriasis. J Invest Dermatol. 2020;140(7): 1451-1455.e13
- CENTRAL NERVOUS SYSTEM PAIN RESPONSE AND COMPONENTS OF DISEASE ACTIVITY IN RA PATIENTS AFTER TREATMENT WITH CERTOLIZUMAB OR PLACEBO: A POST-HOC ANALYSIS FROM THE PRECEPRA TRIAL Ann Rheum Dis. 2020;79 Suppl 1(): 135-136
- MAINTAINED BENEFIT IN HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB PLUS PREDNISONE TAPERING: RESULTS FROM THE OPEN-LABEL, LONG-TERM EXTENSION OF A PHASE 3 RANDOMIZED CONTROLLED TRIAL Ann Rheum Dis. 2020;79 Suppl 1(): 1077-1078
- Interleukin-17 Blockade Leads to Shifts from Stage-based Towards Response-based Disease Clusters- Comparative Data from Very Early and Established Psoriatic Arthritis Arthritis Rheumatol. 2020;72 Suppl 10():
- Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study. ACR Open Rheumatol. 2020;2(1): 18-25
- Psoriatic arthritis epidemiology, comorbid disease profiles and risk factors: results from a claims database analysis. Rheumatol Adv Pract. 2020;4(2):
- PREDICTION OF RESPONSE TO CERTOLIZUMAB PEGOL TREATMENT BY FUNCTIONAL MRI OF THE BRAIN: AN INTERNATIONAL, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (PRECEPRA) Ann Rheum Dis. 2020;79 Suppl 1(): 952-952
- Common RUNX3 missense variant contributes to psoriatic arthritis by affecting splicing and modifying signaling, activation and differentiation of T-cells Eur J Hum Genet. 2020;28 Suppl 1(SUPPL 1): 314-315
- Time to Flare in Patients With New-Onset Versus Relapsing Giant Cell Arteritis Treated With Tocilizumab or Placebo Plus Prednisone Tapering: 3-Year Results From a Randomized Controlled Phase 3 Trial Swiss Med Wkly. 2020;(): 5S-5S
- Similar Impact of Psoriatic Arthritis and Rheumatoid Arthritis on Objective and Subjective Parameters of Hand Function Arthritis Rheumatol. 2020;72 Suppl 10():
- IMPACT OF METHOTREXATE ON DISEASE PATTERN IN ACTIVE PSORIATIC ARTHRITIS PATIENTS ELIGIBLE FOR A RANDOMIZED CLINICAL TRIAL WITH USTEKINUMAB: COMPARATIVE BASELINE DATA FROM MULTICENTRE INVESTIGATOR-INITIATED MUST TRIAL Ann Rheum Dis. 2020;79 Suppl 1(): 773-773
- Polyautoimmunity and Major Organ Involvement Prevalence in Sjogren's Syndrome: Thyroid, Liver, Lung and Kidney as Targets. a Single Center Cross Sectional Study Arthritis Rheumatol. 2019;71():
- Circulating calprotectin (S100A8/A9) is higher in rheumatoid arthritis patients that relapse within 12 months of tapering anti-rheumatic drugs Arthritis Res Ther. 2019;21(1):
- SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS IN PSORIATIC ARTHRITIS: FINAL 5-YEAR EFFICACY AND SAFETY RESULTS FROM THE FUTURE 1 PHASE 3 TRIAL Rheumatology (Oxford). 2019;58 Suppl 3(): 151-151
- Factors Associated with Persistent Drug-free Remission in Patients with Rheumatoid Arthritis Arthritis Rheumatol. 2019;71():
- FACTORS ASSOCIATED WITH PERSISTENT DRUG-FREE REMISSION IN PATIENTS WITH RHEUMATOID ARTHRITIS Ann Rheum Dis. 2019;78(): 730-730
- Seculdnumab efficacy in psoriatic arthritis: individual patient meta analysis of four phase 3 trials in 2049 patients J Eur Acad Dermatol Venereol. 2019;33 Suppl 3(): 83-84
- COMPARATIVE CHANGE IN QUALITY OF LIFE MEASURES IN PRECLINICAL AND ESTABLISHED PSORIATIC ARTHRITIS PATIENTSUNDER SECUKINUMAB TREATMENT. DATA DERIVED FROM THE PROSPECTIVE OPEN LABEL PSARTROS STUDY Ann Rheum Dis. 2019;78(): 1845-1845
- Cost-effective Tapering Algorithm in Patients with Rheumatoid Arthritis: Combination of Multibiomarker Disease Activity Score and Autoantibody Status. J Rheumatol. 2019;46(5): 460-466
- THE ANTI-RO52 PREVALENCE IN THE SJOGREN'S SYNDROME PICTURE: A SINGLE CENTER CROSS SECTIONAL STUDY Ann Rheum Dis. 2019;78(): 1180-1180
- Interleukin 17 Blockade in Psoriasis Patients with Subclinical Joint Inflammation- Prospective Open Study to Influence the Course of the Disease by means of Secukinumab J Dtsch Dermatol Ges. 2019;17(): 127-128
- PHYSICAL FUNCTION IN RA PATIENTS IN REMISSION UNDERGOING TAPERING AND/OR STOPPING OF DMARDS Ann Rheum Dis. 2019;78(): 321-322
- POLYAUTOIMMUNITY AND MAJOR ORGAN INVOLVEMENT PREVALENCE IN SJOGREN'S SYNDROME: THYROID, LIVER, LUNG AND KIDNEY AS TARGETS. A SINGLE CENTER CROSS SECTIONAL STUDY Ann Rheum Dis. 2019;78(): 1744-1745
- [Actual Treatment Options for Giant Cell Arteritis]. Dtsch Med Wochenschr. 2019;144(9): 595-600
- Analyses of association of psoriatic arthritis and psoriasis vulgaris with functional NCF1 variants. Rheumatology (Oxford). 2019;58(5): 915-917
- Transcription factor Fra-1 targets arginase-1 to enhance macrophage-mediated inflammation in arthritis. J Clin Invest. 2019;129(7): 2669-2684
- Association analyses of functional NCF1 variants in psoriatic arthritis and psoriasis vulgaris Eur J Hum Genet. 2019;27(): 125-125
- A SET OF INFLAMMATORY MARKERS ALLOWING TO DETECT SYSTEMIC INFLAMMATION IN PSORIATIC SKIN, ENTHESEAL AND JOINT DISEASE IN THE ABSENCE OF CRP AND THEIR LINK TO CLINICAL DISEASE MANIFESTATION Ann Rheum Dis. 2019;78(): 175-176
- Sensitivity and Specificity of Autoantibodies Against CD74 in Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2019;71(5): 729-735
- Serum Calprotectin Is a Prognostic Marker for Drug-Free Remission in RA Arthritis Rheumatol. 2019;71():
- Resolution of Vascular Inflammation in Patients with Giant Cell Arteritis Receiving Glucocorticoids, Methotrexate or Tocilizumab Treatment: Data from the Italian/German RIGA Study Arthritis Rheumatol. 2019;71():
- Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation-data from the prospective IVEPSA study. Arthritis Res Ther. 2019;21(1):
- RESOLUTION OF VASCULAR INFLAMMATION IN PATIENTS WITH GIANT CELL ARTERITIS RECEIVING GLUCOCORTICOIDS, METHOTREXATE OR TOCILIZUMAB TREATMENT-DATA FROM THE ITALIAN/GERMAN RIGA STUDY Ann Rheum Dis. 2019;78(): 591-591
- The anti-Ro52 Prevalence in the Sjogren's Syndrome Picture: A Single Center Cross Sectional Study Arthritis Rheumatol. 2019;71():
- Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients Arthritis Res Ther. 2019;21():
- SIZE MATTERS - EXTENT OF MONOSODIUM URATE DEPOSITS BUT NOT SERUM URATE LEVEL PREDICTS COMPLETE RESOLUTION OF MONOSODIUM URATE CRYSTAL DEPOSITS IN PATIENTS WITH GOUT Ann Rheum Dis. 2019;78(): 1295-1296
- ACUTE PHASE REACTANT LEVELS AND PREDNISONE DOSES AT DISEASE FLARE IN PATIENTS WITH GIANT CELL ARTERITIS: PROSPECTIVE DATA FROM THE GIACTA TRIAL Rheumatology (Oxford). 2019;58():
- The ageing joint-standard age- and sex-related values of bone erosions and osteophytes in the hand joints of healthy individuals. Osteoarthritis Cartilage. 2019;27(7): 1043-1047
- MICRO-STRUCTURAL CHANGES ASSOCIATED WITH ANTI-CITRULLINATED VIMENTIN AUTOIMMUNITY IN RA-AT-RISK INDIVIDUALS PRECIPITATE THE ONSET OF RHEUMATOID ARTHRITIS Ann Rheum Dis. 2019;78(): 133-133
- THE PHYSIOLOGICAL FINGER JOINT ARCHITECTURE - AGE-RELATED INCREASE OF EROSIONS AND OSTEOPHYTES IN THE JOINTS OF HEALTHY INDIVIDUALS Ann Rheum Dis. 2019;78(): 602-603
- Psoriatic Arthritis - Epidemiology, Incidence Rate in Psoriasis Patients, Comorbidity Profiles and Risk Factor Analysis Arthritis Rheumatol. 2019;71 Suppl 10():
- HAND FUNCTION IS IMPAIRED IN PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND PSORIASIS COMPARED TO HEALTHY CONTROLS Ann Rheum Dis. 2019;78(): 2126-2126
- IMPACT OF PRIMARY HAND OSTEOARTHRITIS ON MICROSTRUCTURE AND BIOMECHANICS IN FINGER JOINTS Ann Rheum Dis. 2019;78(): 1868-1868
- Time to Flare in Patients with New-Onset versus Relapsing Giant Cell Arteritis Treated with Tocilizumab or Placebo Plus Prednisone Tapering: 3-Year Results from a Randomized Controlled Phase 3 Trial Arthritis Rheumatol. 2019;71 Suppl 10():
- EFFECTS OF BASELINE PREDNISONE DOSE ON REMISSION AND DISEASE FLARE IN PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB IN THE GIACTA TRIAL Rheumatology (Oxford). 2019;58():
- SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: LONG-TERM (4-YEAR) DATA FROM A PHASE 3 STUDY J Clin Rheumatol. 2019;25 Suppl 3(): S5-S5
- Maintained Benefit in Health-Related Quality of Life of Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone Tapering: Results from the Open-Label, Long-Term Extension of a Phase 3 Randomized Controlled Trial Arthritis Rheumatol. 2019;71 Suppl 10():
- Identification of Circulating MicroRNA Signatures in Patients with Psoriasis and Psoriatic Arthritis to Develop Novel Strategies for Early Diagnosis of a Bone and Joint Involvement Arthritis Rheumatol. 2019;71():
- INHIBITION OF ARGINASE-1 EXPRESSION BY THE TRANSCRIPTION FACTOR FRA-1 IN MACROPHAGES EXACERBATES RHEUMATOID ARTHRITIS INFLAMMATION Ann Rheum Dis. 2019;78(): A27-A27
- Comparison of the effects of tocilizumab monotherapy and adalimumab in combination with methotrexate on bone erosion repair in rheumatoid arthritis. Ann Rheum Dis. 2019;78(9): 1186-1191
- SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS IN PSORIATIC ARTHRITIS: FINAL 5 YEAR EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL Ann Rheum Dis. 2019;78 Suppl 2(): 917-917
- Long-Term Outcome of Tocilizumab for Patients with Giant Cell Arteritis: Results from Part 2 of a Randomized Controlled Phase 3 Trial Arthritis Rheumatol. 2019;71 Suppl 10():
- The Role of Dietary Fiber in Rheumatoid Arthritis Patients: A Feasibility Study Nutrients. 2019;11(10):